Chronic Lymphocytic Leukemia News

Expert Discusses Ongoing Advances in CLL - OncLive



OncLive
 
Expert Discusses Ongoing Advances in CLL 
OncLive
Over the past several years, there have been several key developments in the treatment landscape for patients with chronic lymphocytic leukemia (CLL), particularly with the approvals of novel agents such as ibrutinib (Imbruvica) and venetoclax ...

and more » 


A Personalized Era in Chronic Lymphocytic Leukemia Treatment - Curetoday.com



Curetoday.com
 
A Personalized Era in Chronic Lymphocytic Leukemia Treatment 
Curetoday.com
Brian Koffman, M.D., a family doctor and medical director of the CLL Society, a patient-education nonprofit organization, has had CLL for 12 years. ?There's never a good time to have CLL,? Koffman says, ?but if you do have it, there's never been a ...

 


Dr. Wierda Discusses Sequencing New Agents in CLL - OncLive



OncLive
 
Dr. Wierda Discusses Sequencing New Agents in CLL 
OncLive
William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses sequencing new agents in chronic lymphocytic leukemia (CLL). With a plethora of novel agents approved in CLL, ...

 


Chronic Lymphocytic Leukemia Advisor - Cancer Therapy Advisor



Cancer Therapy Advisor
 
Chronic Lymphocytic Leukemia Advisor 
Cancer Therapy Advisor
NFATC1 activation, which occurs downstream of B cell receptor signaling, prevents apoptosis of chronic lymphocytic leukemia (CLL) cells and may represent a therapeutic target in the relapsed/refractory disease setting, according to a paper published in ...

 


TG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase 3 Trial - GlobeNewswire (press release)



Press Telegraph
 
TG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase 3 Trial 
GlobeNewswire (press release)
UNITY-CLL is a global Phase 3 randomized controlled clinical trial in patients with Chronic Lymphocytic Leukemia (CLL) that includes two key objectives: first, was to demonstrate contribution of each agent in the TG-1101 (ublituximab) + TGR-1202 ...
TG stumbles on FDA feedback for cancer combo BioPharma Dive
Enrollment complete in TG's late-stage study TG-1101/TG-1202 combo in CLL Seeking Alpha
Why TG Therapeutics Is Tumbling 15% Today Motley Fool

all 58 news articles » 


TG Therapeutics Provides Update On FDA Meeting For GENUINE Phase 3 Trial - Clinical Leader



TG Therapeutics Provides Update On FDA Meeting For GENUINE Phase 3 Trial 
Clinical Leader
The Phase 3 GENUINE study is a randomized, open label, multicenter clinical trial to evaluate the safety and efficacy of TG-1101 (ublituximab) plus ibrutinib compared to ibrutinib alone in adult patients with high risk Chronic Lymphocytic Leukemia (CLL ...

and more » 


Examining the Safety of CLL Medication - Curetoday.com



Examining the Safety of CLL Medication 
Curetoday.com
OVER THE LAST FEW years, significant advances were made in the treatment of patients with chronic lymphocytic leukemia (CLL). Several novel therapies, most of them oral, have now been approved by the Food and Drug Administration. These include ...

 


Neurotoxicity After CAR T-cell Therapy May Be Associated With ... - Oncology Nurse Advisor



Oncology Nurse Advisor
 
Neurotoxicity After CAR T-cell Therapy May Be Associated With ... 
Oncology Nurse Advisor
Patients with endothelial activation prior to lymphodepletion chemotherapy may have an increased risk of adverse events after undergoing CAR T-cell therapy ...

and more » 


MRD-Adapted Therapy Approach Yields Good Results in CLL Patients - Cancer Network



MRD-Adapted Therapy Approach Yields Good Results in CLL Patients 
Cancer Network
Abbreviated chemotherapy is as effective as a full course in patients with chronic lymphocytic leukemia (CLL) who achieve early minimal residual disease?negative complete responses (MRD-negative CRs), according to a phase II trial. ?Flow cytometry ...

 


FDA Grants Priority Review to Durvalumab for Locally Advanced Unresectable NSCLC - OncLive



OncLive
 
FDA Grants Priority Review to Durvalumab for Locally Advanced Unresectable NSCLC 
OncLive
MEDI4736-NHL-001, exploring the drug as a monotherapy in patients with lymphoma or chronic lymphocytic leukemia, and MEDI4736-DLBCL-001, assessing durvalumab in combination with R-CHOP or R2 CHOP, where also given a partial hold. Patients ...

and more »